FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
FORMULA JEAN FRANCOIS
25 FIRST STREET, SUITE 303
CAMBRIDGE MA 02141

2. Issuer and Ticker Symbol
HORIZON PHARMA, INC. [HZNP]

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2012

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
X Director
X 10% Owner

6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Security Code</th>
<th>Amount</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>COMMON STOCK</td>
<td>03/02/2012</td>
<td>P</td>
<td>828,443</td>
<td>$3.6212</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Derivative Security</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Securities Acquired or Disposed Of (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Exercisable and Expiration Date (Month/Day/Year)</th>
<th>Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>Price of Derivative Security (Instr. 5)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 6)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warrants to Purchase Common Stock</td>
<td>4.308</td>
<td>03/02/2012</td>
<td></td>
<td>A or D</td>
<td>03/02/2012</td>
<td>Common Stock</td>
<td>$3,6212 (2)</td>
<td>I</td>
<td>See Footnote (3)</td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. Includes 789,828 shares of common stock purchased at $4.39 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

2. Includes 3,516,377 shares of common stock purchased at $4.39 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

3. Includes 3,516,377 shares of common stock purchased at $4.39 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

4. For each share of common stock of the Issuer purchased in the financing, each purchaser received a warrant to purchase 0.25 of a share of common stock of the Issuer.

5. Includes warrants to purchase 197,456 shares of common stock purchased at $4.308 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

6. Includes warrants to purchase 3,616 shares of common stock purchased at $4.308 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

7. Includes warrants to purchase 3,616 shares of common stock purchased at $4.308 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

8. Includes warrants to purchase 197,456 shares of common stock purchased at $4.308 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

9. Includes warrants to purchase 3,616 shares of common stock purchased at $4.308 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

10. Includes warrants to purchase 197,456 shares of common stock purchased at $4.308 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

11. Includes warrants to purchase 3,616 shares of common stock purchased at $4.308 (the closing bid price of the Issuer's common stock on 2/28/2012) and (ii) 80,031.25.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.